We are proud to inform you about two SAKK trials presented during the ESMO Breast Cancer 2019 Congress, May 2-4, Berlin, Germany.

The abstract listed below has been accepted for Proffered Paper (Oral):

Abstract title: Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG) 

The abstract is also published in the ESMO Breast Cancer 2019 Congress Abstract Book, a supplement to the official ESMO journal Annals of Oncology. 

The abstract listed below has been accepted for Poster display session:

SAKK 21/12: A stratified, multicenter phase II trial of transdermal CR1447 in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer 

Further information can be found on the ESMO Breast Cancer 2019 website.